Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Monday, November 18, 2019  Spokane, Washington  Est. May 19, 1883
News >  Business

GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro

In this July 24, 2013 photo, a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. (Eugene Hoshiko / Associated Press)
In this July 24, 2013 photo, a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. (Eugene Hoshiko / Associated Press)
Associated Press

Shares of Tesaro soared Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.

Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula. That represents a premium of more than 60 percent to the stock’s $46.38 closing price Friday. The total deal price includes Tesaro’s net debt.

Glaxo CEO Emma Walmsley said in a statement that the deal will accelerate growth of the British drugmaker’s oncology business.

Zejula brought in $166 million in revenue in the first nine months of this year, with third-quarter sales growing more than 60 percent.

Glaxo expects the deal to close in the first quarter.

Shares of Waltham, Massachusetts-based Tesaro Inc. jumped nearly 59 percent to $73.60 in morning trading.

Subscribe to the Morning Review newsletter

Get the day’s top headlines delivered to your inbox every morning by subscribing to our newsletter.

You have been successfully subscribed!
There was a problem subscribing you to the newsletter. Double check your email and try again, or email webteam@spokesman.com